These Biotech Companies Are Facing Setbacks, but Investors Shouldn't Worry
Rupert is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
Historically known as a defensive sector, biotech stocks have recently come under pressure as patent expirations, regulation, and litigation hit the industry.
Most recently, executives working for the U.K.-based GlaxoSmithKline (NYSE: GSK) in China have been accused of, and confessed to, serious corruption and tax-related offences. Glaxo is not alone, as Chinese authorities are currently undertaking a sweeping analysis of foreign firms operating in the country in an attempt to weed out corruption. The allegations include bribing officials in order to increase sales and open up new sales channels for the company.
Unfortunately, GlaxoSmithKline itself disagrees with these allegations, stating that it has monitored the situation in China and found no evidence of corruption or wrongdoing among its employees. These allegations also follow similar claims that Glaxo's sales staff showered Chinese doctors with cash for promoting the company's Botoxanti wrinkle treatment. Allegedly, Glaxo's marketing staff had planned to pay doctors $490 for meeting prescription quotas.
Financially, these allegations will not hurt Glaxo significantly in the short-term as only 3% of the company's revenue comes from the Chinese market. However, this market is a key area of growth for the company and while sales slow down in other markets, rising sales in China have been offsetting some of the decline. However, if the company faces a selling ban in the country, it could hold back future growth unless some agreement is made with the Chinese authorities.
There are other problems in the industry
Indeed, at the end of the first quarter, Pfizer cut its full-year diluted EPS guidance from $1.50-$1.65 to $1.44-$1.59. Pfizer blamed part of this decline on currency fluctuations, in particular, the weak yen and the strong U.S. dollar. Unfortunately, these issues are not going to disappear anytime soon as the yen has only become weaker and the dollar stronger.
In addition, the company has been suffering from declining sales due to rising competition and patent expirations. Sales of Pfizer's key Prevnar 13 drug only raked in $440 million in sales during the first quarter, well short of estimates (10% less) and sales of the company's second most popular drug, Enbrel, slid 2%. However, the well-known Viagra sold about 10% more than analysts expected.
Unfortunately, it does not seem that Pfizer's new drugs coming to market will be enough to offset the company's declining sales from existing products. Indeed, sales of the company's new and highly anticipated blood thinner, Eliquis, and rheumatoid arthritis treatment, Xeljanz, were not reported in first-quarter results, but Pfizer's Eliquis partner, Bristol-Myers Squibb, reported sales of $22 million for its share of the drug, about 50% below analyst estimates.
Merck was also hit hard by a rapid drop-off in sales during the first quarter. The company's leading asthma drug, Singulair, saw sales drop a staggering 75% year-on-year. Moreover, the company's Januvia product franchise failed to meet targets and sales slipped 4%. The company's sales did grow in some areas, however. Sales of the company's HIV drug grew 8% and cervical cancer vaccine Gardasil expanded 30%. That said, Merck still expects revenue to come in 5% below initial estimates for the year.
Merck and Pfizer are taking action
As sales are rapidly declining, Merck and Pfizer have decided to undertake huge buyback programs, reinvesting their huge cash piles and free cash flows, returning the cash to shareholders, which should, to some extent, offset the decline in sales by reducing the number of shares in issue and boosting EPS.
Although this is only an aesthetic change and the companies' underlying sales are still under pressure, these buybacks should hold up stock prices while both Merck and Pfizer develop their drug pipelines, bring new products to market, and streamline operations.
In addition, these buybacks put both Pfizer and Merck in the top ten for the best shareholder returns in the S&P 500. Indeed, Merck is set to return around $8.20 per share, an indicative yield of 17%! Including dividends, Pfizer is set to return $21 billion to shareholders this year, around $2.80 per share, a yield of 10%.
All in all, the biotechnology sector is not the risk-free profit machine it once was. Having said that, these companies are some of the biggest (Pfizer is the biggest) drug manufacturers in the world, a position that is hard to achieve and any setback is only likely to be short-lived.
Still, Pfizer and Merck are set to return huge amounts of cash to shareholders this year and any setback for Glaxo in China should only be temporary.
Obamacare will undoubtedly have far-reaching effects. The Motley Fool’s new free report, “Everything You Need to Know About Obamacare,” lets you know how your health insurance, your taxes, and your portfolio could be impacted. Click here to read more.
Fool contributor Rupert Hargreaves has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Is this post wrong? Click here. Think you can do better? Join us and write your own!